Evidence map›Paper›PMID 39192264›Full record

ArticleJournal of nanobiotechnology2024

Endogenous capsid-forming protein ARC for self-assembling nanoparticle vaccines.

Yu Li, Xiaofan Zhao, Jiaqi Tang, Mengran Yi, Xiaodong Zai, Jun Zhang, Gong Cheng, Yilong Yang, Junjie Xu

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu LiNew Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China.
Xiaofan ZhaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
Jiaqi TangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
Mengran YiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
Xiaodong ZaiLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
Jun ZhangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China.
Gong ChengNew Cornerstone Science Laboratory, Tsinghua-Peking Joint Center for Life Sciences, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China. gongcheng@mail.tsinghua.edu.cn.
Yilong YangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China. yyl_pku@126.com.
Junjie XuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, 100071, China. xujunjie@sina.com.

Funding

Beijing Nova Program of Science and Technology 20220484127National Natural Science Foundation of China 82171818
6 · The paper itself

Abstract

The application of nanoscale scaffolds has become a promising strategy in vaccine design, with protein-based nanoparticles offering desirable avenues for the biocompatible and efficient delivery of antigens. Here, we presented a novel endogenous capsid-forming protein, activated-regulated cytoskeleton-associated protein (ARC), which could be engineered through the plug-and-play strategy (SpyCatcher3/SpyTag3) for multivalent display of antigens. Combined with the self-assembly capacity and flexible modularity of ARC, ARC-based vaccines elicited robust immune responses against Mpox or SARS-CoV-2, comparable to those induced by ferritin-based vaccines. Additionally, ARC-based nanoparticles functioned as immunostimulants, efficiently stimulating dendritic cells and facilitating germinal center responses. Even without adjuvants, ARC-based vaccines generated protective immune responses in a lethal challenge model. Hence, this study showed the feasibility of ARC as a novel protein-based nanocarrier for multivalent surface display of pathogenic antigens and demonstrated the potential of exploiting recombinant mammalian retrovirus-like protein as a delivery vehicle for bioactive molecules.

Indexed as

Capsid ProteinsNanoparticlesNanovaccinesAnimalsCytoskeletal ProteinsDendritic CellsFemaleHumansMiceMice, Inbred BALB CNerve Tissue Proteinsactivity regulated cytoskeletal-associated proteinCapsid ProteinsCytoskeletal ProteinsNanovaccinesNerve Tissue ProteinsARCImmunostimulantProtein nanoparticlesSelf-assemblyVaccines

Identifiers

PMID39192264
PMCPMC11348728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.